Correlation Between WUXI BIOLOGICS and CITIUS PHARMAC

Can any of the company-specific risk be diversified away by investing in both WUXI BIOLOGICS and CITIUS PHARMAC at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining WUXI BIOLOGICS and CITIUS PHARMAC into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between WUXI BIOLOGICS UNSPADR2 and CITIUS PHARMAC DL, you can compare the effects of market volatilities on WUXI BIOLOGICS and CITIUS PHARMAC and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in WUXI BIOLOGICS with a short position of CITIUS PHARMAC. Check out your portfolio center. Please also check ongoing floating volatility patterns of WUXI BIOLOGICS and CITIUS PHARMAC.

Diversification Opportunities for WUXI BIOLOGICS and CITIUS PHARMAC

-0.39

Correlation Coefficient

WUXI BIOLOGICS  CITIUS PHARMAC

Very good diversification

The 3 months correlation between WUXI and CITIUS is -0.39. Overlapping area represents the amount of risk that can be diversified away by holding WUXI BIOLOGICS UNSPADR2 and CITIUS PHARMAC DL in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CITIUS PHARMAC DL and WUXI BIOLOGICS is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on WUXI BIOLOGICS UNSPADR2 are associated (or correlated) with CITIUS PHARMAC. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CITIUS PHARMAC DL has no effect on the direction of WUXI BIOLOGICS i.e., WUXI BIOLOGICS and CITIUS PHARMAC go up and down completely randomly.

Pair Corralation between WUXI BIOLOGICS and CITIUS PHARMAC

Assuming the 90 days trading horizon WUXI BIOLOGICS UNSPADR2 is expected to generate 0.7 times more return on investment than CITIUS PHARMAC. However, WUXI BIOLOGICS UNSPADR2 is 1.43 times less risky than CITIUS PHARMAC. It trades about 0.18 of its potential returns per unit of risk. CITIUS PHARMAC DL is currently generating about -0.2 per unit of risk. If you would invest  252.00  in WUXI BIOLOGICS UNSPADR2 on September 15, 2024 and sell it today you would earn a total of  176.00  from holding WUXI BIOLOGICS UNSPADR2 or generate 69.84% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

WUXI BIOLOGICS UNSPADR2  vs.  CITIUS PHARMAC DL

WUXI BIOLOGICS UNSPADR2

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in WUXI BIOLOGICS UNSPADR2 are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite nearly unsteady basic indicators, WUXI BIOLOGICS reported solid returns over the last few months and may actually be approaching a breakup point.

CITIUS PHARMAC DL

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days CITIUS PHARMAC DL has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Pair Trading with WUXI BIOLOGICS and CITIUS PHARMAC

The main advantage of trading using opposite WUXI BIOLOGICS and CITIUS PHARMAC positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if WUXI BIOLOGICS position performs unexpectedly, CITIUS PHARMAC can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CITIUS PHARMAC will offset losses from the drop in CITIUS PHARMAC's long position.

The idea behind WUXI BIOLOGICS UNSPADR2 and CITIUS PHARMAC DL pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.